title: Usefulness of serum p53 antibody measurement in colorectal cancer: an examination of 1384 primary colorectal cancer patients.
abstract: OBJECTIVE
  Recently, the serum p53 antibody (S-p53Ab) has been used widely in clinical practice as a tumor marker for colorectal cancer (CRC). However, no large-scale studies have examined the usefulness of serial measurements of S-p53Ab or have established the relationship of this parameter with the clinicopathological factors of CRC.
  
  
  METHODS
  An ELISA for S-p53Ab was performed for 1384 primary CRC patients, and the results were categorized by the clinicopathological factors.
  
  
  RESULTS
  The S-p53Ab positivity rate was 24.1 %, and was significantly higher in Stage III-IV than in Stage 0-II cases. However, no relationship was seen with the serum carcinoembryonic antigen (CEA) or carbohydrate antigen 19-9 (CA19-9) levels. The addition of the S-p53Ab assay to the CEA and CA19-9 measurements increased the overall diagnostic sensitivity to 50.9 % (CEA and/or CA19-9: 37.3 %). In patients who had undergone complete resection, S-p53Ab positivity was associated with a decrease in the relapse-free survival (p = 0.012), but it was not independent prognostic indicator. S-p53Ab positivity had no influence on the cancer-specific survival.
  
  
  CONCLUSIONS
  The S-p53Ab positivity rate was higher than the positivity rates for CEA and/or CA19-9 in Stage 0-I CRC patients. Combining the use of the three tumor marker tests is a potentially effective method for detecting even early-stage CRC.
authors: Department of Surgery, Niigata Cancer Center Hospital, 2-15-3 Kawagishicho, Chuo-ku, Niigata, 951-8566, Japan, tetsuji-yama@blue.ocn.ne.jp.
authors: Tetsuji
authors: T
authors: Yamaguchi
authors: Yasumasa
authors: Y
authors: Takii
authors: Satoshi
authors: S
authors: Maruyama
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000906:Antibodies / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D015179:Colorectal Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology; D042241:Early Diagnosis; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012680:Sensitivity and Specificity; D015996:Survival Rate; D016159:Tumor Suppressor Protein p53 / Q000276:immunology*; D055815:Young Adult
chemical_list: D000906:Antibodies; D014408:Biomarkers, Tumor; D016159:Tumor Suppressor Protein p53
references: Dig Dis Sci. 2000 Jan;45(1):122-8
references: 10695624
references: Oncol Rep. 1998 Jul-Aug;5(4):871-4
references: 9625835
references: Cancer. 2003 Feb 1;97(3):682-9
references: 12548611
references: J Hepatol. 1997 Oct;27(4):661-8
references: 9365042
references: Int J Colorectal Dis. 2004 Mar;19(2):114-20
references: 14634775
references: Lancet. 1995 Mar 11;345(8950):621-2
references: 7898180
references: Surg Today. 2012 Jan;42(2):164-8
references: 22075664
references: Scand J Gastroenterol. 1997 Nov;32(11):1147-51
references: 9399397
references: Int J Cancer. 1994 Aug 15;58(4):480-7
references: 8056443
references: Int J Cancer. 2001 Dec 15;94(6):859-63
references: 11745489
references: Cancer. 1996 Nov 15;78(10):2146-52
references: 8918407
references: J Clin Oncol. 1999 Feb;17(2):593-9
references: 10080604
references: Int J Colorectal Dis. 2008 Jun;23(6):595-600
references: 18330580
references: Int J Cancer. 1997 Jan 6;70(1):46-51
references: 8985089
references: Br J Cancer. 1995 Sep;72(3):637-41
references: 7669574